Metraipolis › archive › dc_f21eee0cfdab

How does pulmonary function impact QoL in patients with locally advanced NSCLC treated with chemoradiotherapy and durvalumab? — Europe PMC PMID:41854264

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41854264
DOI
10.2340/1651-226x.2026.45040
License (as archived)
solo-consultazione
Archived
2026-10-08T00:57:38.637Z
SHA-256 of the archived text
d07bac24796db3e4576ad162d355933a60446eb8d718c073417d63da840b2311
Stable URL of this page
https://metraipolis.com/documento/dc_f21eee0cfdab

How to cite

How does pulmonary function impact QoL in patients with locally advanced NSCLC treated with chemoradiotherapy and durvalumab? — Europe PMC PMID:41854264 — Europe PMC (en), https://europepmc.org/article/MED/41854264 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_f21eee0cfdab (Metraipolis archive dc_f21eee0cfdab, sha256 d07bac24796db3e4576ad162d355933a60446eb8d718c073417d63da840b2311)
BibTeX
@misc{dcf21eee0cfdab,
  title = {How does pulmonary function impact QoL in patients with locally advanced NSCLC treated with chemoradiotherapy and durvalumab? — Europe PMC PMID:41854264},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41854264},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_f21eee0cfdab; sha256 d07bac24796db3e4576ad162d355933a60446eb8d718c073417d63da840b2311},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41854264. Agents can read the archived copy with the MCP tool read_document.